Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease. [PDF]
Front PharmacolLi X, Zhang J, Wei B, Tong H.
europepmc +1 more source
Medicinal Chemistry Review of the NEET Protein Family. [PDF]
ChemMedChemGeldenhuys WJ +10 more
europepmc +1 more source
Residual bile flow shapes PPARγ-mediated antifibrotic responses in experimental segmental cholestasis. [PDF]
Sci RepGonçalves JO +10 more
europepmc +1 more source
Fluid retention versus cardio protection: rethinking pioglitazone. [PDF]
Ann Med Surg (Lond)Imran G, Ali U, Mahato RK.
europepmc +1 more source
Personalized Diabetes Therapy Part 2-Individual Diabetes Treatment (Standard of Care Plus, SOC+). [PDF]
J Pers MedJantz J, Pfützner A.
europepmc +1 more source
Comparative Efficacy of Pioglitazone, Saroglitazar, and Silymarin on Biochemical and Histopathological Hepatic Outcomes in a Wistar Rat Model of Non-alcoholic Fatty Liver Disease and Their Correlation With Insulin Sensitivity. [PDF]
CureusJain I, Nath R, Kumar M, Pal R, Dixit R.
europepmc +1 more source
Observational studies on the association of outpatient antidiabetic medication use and COVID-19 outcomes: are the findings more relevant to diabetes management than to COVID-19 pathology? A mini-review. [PDF]
Front Clin Diabetes HealthcDimnjaković J, Buble T, Brborović O.
europepmc +1 more source
Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasias. [PDF]
Front PharmacolHarrer DC +5 more
europepmc +1 more source
PPAR-γ activation by pioglitazone inhibits microglia-mediated neuroinflammation and alleviates disease in neuromyelitis optica spectrum disorders. [PDF]
Acta Neuropathol CommunYick LW +6 more
europepmc +1 more source
Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells. [PDF]
Ann HematolAtef B +4 more
europepmc +1 more source